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Nephrotoxic Effects of Drugs
Azade Sari
Abstract
Drug-induced nephrotoxicity is a renal dysfunction that occurs as a result of 
exposure to nephrotoxic drugs. It is a common problem in certain clinical situations 
such as underlying renal dysfunction, cardiovascular disease, diabetes, and sepsis. 
Drugs can cause mild to moderate nephrotoxic problems such as intrarenal obstruc-
tion, interstitial nephritis, nephrotic syndrome, acid-base and fluid-electrolyte 
disturbances, alteration in intraglomerular hemodynamics, inflammatory changes 
in renal tubular cells, tubulointerstitial disease, and renal scarring leading to acute 
or chronic kidney injury. Therefore, early detection of adverse effects of drugs as 
well as the clinical history of the patient, basic renal functions, drug-related risk 
factors, and nephrotoxic drug combinations must be well known in order to prevent 
drug-induced nephrotoxicity and progression to end-stage renal disease.
Keywords: nephrotoxicity, drugs, drug interaction, acute kidney injury,  
chronic kidney injury, prevention strategies, nephrotoxicity biomarkers
1. Introduction
Acute kidney injury is the deterioration of the renal function over hours or days, 
resulting in the accumulation of toxic wastes and the loss of internal homeostasis. It 
can be caused by numerous etiologies [1, 2], and medications are a relatively com-
mon cause of kidney injury among these injuries [3]. Drug-induced nephrotoxicity 
is a renal dysfunction that occurs as a result of direct or indirect exposure to neph-
rotoxic prescribed drugs, over-the-counter products, diagnostic agents, or alterna-
tive/complementary products (herbal remedies, natural products, nutritional 
supplements) that are widely available at most health food stores [3, 4]. Drug-
induced nephrotoxicity is an extremely common condition and is responsible for a 
variety of pathological effects on the kidneys [4]. Nephrotoxicity most commonly 
affects tubulointerstitial compartment and manifests either acute tubular injury 
(ATI) or acute interstitial nephritis (AIN). There is a growing incidence of drug-
induced glomerular disease, including direct cellular injury and immune-mediated 
injury [5]. However, kidney disease does not develop in all patients exposed to the 
various potential nephrotoxins [3]. The nephrotoxicity of medications, drugs, or 
other ingested substances is a complicated process that involves a combination of 
factors.
Potential nephrotoxic effect of the drug, comorbid diseases or conditions 
(underlying renal dysfunction, cardiovascular disease, diabetes, immunologic 
diseases, sepsis, etc.), genetic determinants of drug metabolism and transport, 
immune response genes, drug dose and duration of therapy, drug characteristics 
(solubility, structure and charge), combinations of potential nephrotoxic drugs, 
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urine pH, metabolic disturbances, older age (>65 year), and female sex are the com-
mon risk factors for drug-induced nephrotoxicity [1–5].
2. Preventive measures of drug-induced nephropathy
Basic renal functions should be evaluated and patient’s renal functions should be 
considered when prescribing a new drug.
Dosage adjustments of the drugs should be done according to the patient’s basic 
renal functions.
Risk factors for nephrotoxicity must be corrected before initiation of therapy.
Nephrotoxic drug combination should be avoided.
Adequate hydration before and during therapy must be ensured.
Whenever possible, equally effective nonnephrotoxic drugs should be used [4].
3. Biomarkers of drug-induced kidney injury
Early detection of drug-induced kidney injury is vital. Traditional biomark-
ers such as creatinine (Cr) and blood urea nitrogen (BUN) are insensitive for 
monitoring renal safety. Thus, new biomarkers have been investigated for accurate 
diagnosis, risk assessment, adopting therapy, and improvement of clinical outcome. 
[4, 6–9] Serum Cr can raise in prerenal azotemia without tubular injury, and some 
factors such as muscle mass, total body weight, fluid status, age, gender, race, and 
drugs influence serum Cr levels [8]. There are novel biomarkers that are more sensi-
tive and can detect renal damage earlier than serum BUN and Cr levels [4, 6–9]. It 
is clear that which marker indicates kidney damage, but it is not yet clear when they 
should be measured. Also it is not clear if these biomarkers should be used for clini-
cal decision-making or what should be done when the levels are elevated. Further 
studies are required for the routine clinical use of these biomarkers [8]. Table 1 
lists common novel biomarkers that are under investigation.
3.1 Neutrophil gelatinase-associated lipocalin (NGAL)
NGAL is an acute phase reactant, and it can raise in inflammatory conditions. 
It is expressed by tubular epithelial cells in response to injury and tubulointer-
stitial damage. It can be measured in both plasma and urine [8–13], but for early 
detection of acute kidney injury (AKI), increase in urine NGAL is more specific 
than increase in plasma NGAL [9]. Baseline renal functions, severity of AKI, and 
age influence the level of NGAL. Studies showed that plasma and urine NGAL 
levels rise 2 hours after the injury; thus, it is the strongest predictor of AKI [8, 9]. 
It is more sensitive in ischemic and toxic (tacrolimus, cisplatin, cyclosporine A, 
radiographic contrast agent) AKI. [9] NGAL levels can be a predictor of clinical 
outcomes of AKI (need for dialysis and mortality) [9, 11] and progression of 
chronic kidney disease (CKD) in adults [8, 10, 12, 13]. Urine excretion of NGAL 
may be increased by albuminuria [9].
3.2 Cystatin-C (Cys-C)
Cys-C is a protein that synthesized in all nucleated cells. It is freely filtered 
in the glomerulus and reabsorbed and catabolized completely in the proximal 
tubules without tubular secretion. It is an alternative parameter of serum Cr in the 
measurement of renal function [8–11, 13]. Serum Cys-C levels are not influenced 
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by gender, age, total body weight, muscle mass, or race, but tubular reabsorption is 
decreased by marked albuminuria [9–11]. It is thought to be the best biomarker for 
early kidney injury and more reliable marker of renal function [8, 10, 11].
3.3 Cyclophilins
They are structural proteins and measured in urine and plasma. Elevated levels 
of cyclophilins indicate AKI [11].
3.4 Kidney injury molecule-1 (KIM-1)
KIM-1 is a transmembrane glycoprotein. After ischemic or toxic injury, its levels 
elevate and it helps to distinguish acute tubular nephritis (ATN) from prerenal azo-
temia and CKD. Elevated urine KIM-1 levels are highly specific for kidney injury, 
because it is only expressed in injured kidney [8–13]. Some studies suggest KIM-1 as 
an indicator of AKI transition to CKD, because high levels of KIM-1 are maintained 
during CKD progression [12].
3.5 Interleukin-18 (IL-18)
It is also known as interferon-γ (IFN-γ)-inducing factor and its urinary levels 
rise in ischemic and toxic AKI [9]. It predicts renal parenchymal injury [10]. Its 
Biomarker Source Region specificity Clinical 
application
NGAL Plasma/urine Proximal tubule/distal tubule AKI/CKD
Cyclophilins Urine Glomerulus/proximal tubule AKI
KIM-1 Urine Proximal tubule AKI/CKD
IL-18 Urine Proximal tubule AKI
L-FABP Urine Proximal tubule AKI
H-FABP Plasma/urine Distal tubule AKI
NAG Urine Proximal tubule AKI
α-GST Urine Proximal tubule AKI
π-GST Urine Distal tubule AKI
γ-GT Urine Proximal tubule AKI
Low-molecular-weight proteins
Cystatin-C Urine Glomerulus/proximal tubule AKI
α1-Microglobulin Urine Proximal tubule/glomerulus AKI/CKD
β2-Microglobulin Urine Proximal tubule AKI/CKD
RBP Urine Proximal tubule AKI
Cell cycle arrest proteins
IGFBP-7 Urine Proximal tubule AKI
TIMP-2 Urine Proximal tubule AKI
Clusterin Urine Proximal tubule/distal tubule AKI/CKD
TFF-3 Urine Proximal tubule/distal tubule AKI/CKD
Table 1. 
Summary of novel nephrotoxicity biomarkers.
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levels are higher in patients with ATN. Increased urinary levels of IL-18 are a 
predictor of poor outcome such as death and the need for short-term dialysis [8, 9]. 
According to some studies, urine IL-18 levels increase in contrast-induced AKI [12], 
6–12 hours after administration of the radiocontrast agent [9].
3.6 Cell cycle arrest biomarkers
Insulin-like growth factor-binding protein 7 (IGFBP-7) and tissue inhibitor 
of metalloproteinase-2 (TIMP-2) are the two biomarkers included in this group. 
They are measured in urine and can be used for risk stratification of AKI [8, 9]. 
According to some studies, the most important advantage of these biomarkers is 
that their levels are not affected by comorbid diseases such as CKD, diabetes, and 
sepsis [8].
3.7 Liver-type fatty acid-binding protein (L-FABP)
FABP is a cytoplasmic protein found in all tissues with fatty acid metabolism. 
In kidneys, liver-type (in proximal tubule) and heart-type (in distal tubule) FABP 
present. Studies showed that urinary L-FABP is a useful biomarker in ischemic and 
toxic (especially cisplatin toxicity and contrast-induced nephropathy) AKI  
[9, 10, 12]. Elevated urinary and plasma H-FABP levels are indicator of distal 
tubular injury [10].
3.8 N-acetyl-beta-D glucosaminidase (NAG)
It is an enzyme produced by the proximal tubular cells. It can be found in the 
urine in very small amounts in healthy people. It cannot be filtered by glomerulus; 
thus, elevated levels of urine NAG indicate tubular damage [9, 10, 12]. Studies 
showed that NAG is a useful, sensitive, and early biomarker of contrast-induced 
AKI and high urinary levels correlate with poor outcome [9]. Also, high urinary 
NAG levels have been showed to be an indicator of clinical and subclinical tubular 
damage after chemotherapy [10] and are a sensitive biomarker of acute oxidative 
stress [11].
3.9 Midkine
It is a heparin-binding growth factor. Although not studied well, it may increase 
in contrast-induced AKI [9].
3.10 α- and π-glutathione S-transferase (α-GST, π-GST)
They are cytosolic, microsomal, and membrane-bound enzymes. They are 
detoxification enzymes that present in kidney and many other organs. Some studies 
showed elevation in urine α-GST indicating epithelial necrosis in the proximal 
tubules and π-GST indicating epithelial necrosis in the distal tubules [9–11]. α-GST 
is thought to be a biomarker of proximal tubular necrosis of cisplatin-induced 
injury. α-GST and KIM-1 are sensitive biomarkers for predicting polymyxin-
induced nephrotoxicity [10].
3.11 γ-Glutamil transpeptidase (γGT) and alkaline phosphatase (AP)
They are two enzymes that may increase in urine in proximal tubular epithe-
lial damage [9–11]. Some studies showed increased levels of γGT, 24 hours after 
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contrast administration [9], and some showed that it may be a sensitive biomarker 
of acute paracetamol nephrotoxicity [11].
Alanine amino peptidase (AAP), lactate dehydrogenase (LDH), β-galactosidase, 
β-glucuronidase, and leucine aminopeptidase are the other enzymes that are used 
for nephrotoxicity biomarkers [10, 11].
3.12 β-2-Microglobulin
It is a low-molecular-weight protein. It is normally found in urine but increases 
in tubular injury secondary to antibiotic, analgesic, solvent, heavy metal, or pesti-
cide poisoning. In these conditions, it has been proved to be a sensitive biomarker of 
renal tubular damage [9–13]. But it rapidly degrades in room temperature and urine 
pH < 6; therefore, its utility as a urinary biomarker is limited [12].
3.13 α-1-Microglobulin
It is a low-molecular-weight protein, and elevated urinary levels can be used as a 
biomarker of tubular injury [10–12]. It is resistant to pH changes; thus, it is a sensi-
tive biomarker of proximal tubular dysfunction [12].
3.14 Retinol-binding protein (RBP)
It is a low-molecular-weight protein that functions in vitamin A transportation 
from the liver to other tissues. It is a sensitive biomarker in proximal tubular dam-
age [9–11].
3.15 MicroRNA (miRNA)
Although not demonstrated well, some subgroups of miRNA (miRNA-30a, -30c, 
and -30e) may rise in serum and urine in the states of contrast-induced AKI [9].
3.16 Clusterin
It is a glycoprotein and may be used as a biomarker for cisplatin-induced 
nephrotoxicity [10]. Urinary clusterin levels may increase following drug-induced 
nephrotoxicity [13].
3.17 Trefoil factor 3 (TFF3)
It is another new biomarker of nephrotoxicity that is mainly expressed in kid-
neys. Studies showed marked decrease in urinary TFF3 after nephrotoxic AKI [13].
4. Common nephrotoxic drugs
4.1 Antibiotics
4.1.1 β-Lactam antibiotics
β-Lactam antibiotics include penicillins, cephalosporins, cephamycins, car-
bapenems, monobactams, and β-lactamase inhibitors, and these are among the 
most commonly prescribed antibiotics [14]. β-Lactam antibiotics, especially peni-
cillins and cephalosporins, frequently cause hypersensitivity reactions. Methicillin 
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and nafcillin are the prototypical drugs for hypersensitivity reactions associated 
with AIN. It is generally characterized by acute and severe renal failure. Hematuria, 
proteinuria, leucocyturia, and pyuria are seen in urinary sediment of affected 
patients. Hypersensitivity reactions such as fever, rush, and peripheral eosinophilia 
are commonly seen [5, 14].
Piperacillin-tazobactam and vancomycin must not be used concurrently; they 
may cause AKI. Cephalosporins may exacerbate the renal toxicity of aminoglyco-
sides [14].
4.1.2 Non-β-lactam antibiotics
They can cause AIN. Rifampicin-induced AIN is dose dependent and is com-
monly associated with oliguric acute renal failure, hemolytic anemia, throm-
bocytopenia, and hepatitis. Approximately two-thirds of patients affected by 
rifampin-induced AIN require renal transplantation [5].
4.1.3 Aminoglycosides
Aminoglycosides are antibiotics used in the treatment of Gram-negative and 
Staphylococcus aureus infections [1]. Aminoglycosides commonly cause acute kidney 
injury during therapy. It typically manifests after 5–7 days of therapy. It is described 
as a rise in the plasma creatinine concentration of more than 0.5–1 mg/dL or 50% 
increase in plasma creatinine concentration from baseline [15].
Tubular uptake of aminoglycosides is a saturable process; thus, a single daily 
high dose is preferable to divided low doses. Administration of aminoglycosides by 
this way will cause less nephrotoxic effect [4, 15, 16].
Aminoglycosides primarily affect proximal tubules [1, 16], and patients present 
with acute tubular necrosis, showing features such as nonoliguric acute renal failure 
[4]. Proximal dysfunction leads to loss of enzymes, proteins, glucose, calcium, 
potassium, and magnesium [1]. In some patients, distal tubular segments can be 
affected and this manifests as polyuria and hypomagnesemia. Most patients may 
recover but some progress to irreversible kidney damage, especially if the patient is 
hypovolemic, septic, or catabolic. Aminoglycoside nephrotoxicity risk factors are 
nearly the same as other nephrotoxic agents. In addition to common factors, higher 
creatinine clearances and hypoalbuminemia are also independent risk factors for 
aminoglycoside nephrotoxicity [9].
4.1.4 Polymyxins/colistin
Polymyxins are a group of antibiotics that are used for pan-resistant nosocomial 
infections, especially for Pseudomonas and Acinetobacter spp. They may cause 
nephrotoxicity by IV injection. The nephrotoxicity mechanism is ATN leading to 
acute renal failure (ARF) with hematuria, proteinuria, and oliguria.
According to data, colistin appears more nephrotoxic than polymyxin 
B. Colistin-induced nephrotoxicity may exacerbate by older age, preexisting 
renal insufficiency, hypoalbuminemia, and concomitant use of NSAIDs. There 
are limited data on the risk factors for polymyxin-B associated nephrotoxicity. 
Methoxyflurane and cefazedone may enhance the nephrotoxic effect of poly-
myxin-B. Methoxyflurane-polymyxin-B combination should be avoided, but 
polymyxin-B-cefazedone combination may be used by close monitoring renal 
functions. Also, polymyxin-B may enhance the nephrotoxic effect of bacitracin 
[17, 18].
7Nephrotoxic Effects of Drugs
DOI: http://dx.doi.org/10.5772/intechopen.83644
4.2 Analgesics
Analgesic nephropathy is a CKD characterized by papillary necrosis and chronic 
interstitial nephritis. It is caused by prolonged consumption of analgesic agents. 
Hypertension is a common clinical finding. The major laboratory manifestations are 
hematuria, sterile pyuria, elevation in serum Cr levels, and anemia [19, 20].
4.2.1 Nonsteroidal anti-inflammatory drugs (NSAIDs)
NSAIDs lead to AIN, chronic interstitial nephritis and finally CKD [20, 21]. Risk 
factors that may increase the nephrotoxic effect of NSAIDs are congestive heart 
failure, age > 65 years, and preexisting renal disease [4, 21].
4.2.2 Acetylsalicylic acid (ASA)
When used alone, even if prolonged, acetylsalicylic acid is not thought to cause 
kidney damage. It aggravates the nephrotoxic effects of both phenacetin and acetamin-
ophen; thus, it should not be used simultaneously with these drugs. Acetylsalicylic 
acid and acetaminophen combination leads to papillary necrosis and calcification. 
Acetylsalicylic acid and NSAID combination leads to ischemic injury [20].
4.2.3 Acetaminophen (paracetamol)
Oral and rectal forms of acetaminophen may cause nephrotoxicity with chronic 
overdose [12]. The incidence of renal dysfunction is related to the severity of the acet-
aminophen ingestion [22]. IV forms may cause oliguria in neonates, infants, children, 
and adults [23]. AKI, which is primarily ATN, is manifested by elevations of BUN and 
Cr along with proteinuria, hematuria, and granular and epithelial cell casts on urine 
analyses. Also vascular endothelial damage can occur. It may be used in severe renal 
impairment with caution and dosing must be adjusted. Renal functions spontane-
ously return to baseline within 1–4 weeks. Rarely dialysis may be required. There is no 
evidence that N-acetylcysteine has any protective effect on nephrotoxicity [22, 23].
4.3 5-Aminosalicylates (5-ASAs)
5-ASAs are used to treat inflammatory bowel diseases. They lead hypersensitiv-
ity reactions in multiple organs, especially in kidneys, leading to acute interstitial 
nephritis [5, 24, 25]. During 5-ASA therapy, regular monitoring of renal functions 
is recommended [24]. AIN occurs most commonly during the initial year of therapy 
and it is non-dose-dependent. But in some patients with inflammatory bowel 
disease, AIN may occur as a complication of the disease [5].
4.4 Proton pump inhibitors (PPIs)
Proton pump inhibitors are used to treat acid-related gastrointestinal disorders. 
According to recent studies, many side effects of proton pump inhibitors have been 
reported. One of the side effects of the drug is nephrotoxicity, especially acute 
interstitial nephritis. PPI is thought to be associated with increased chronic kidney 
disease and its progression [5].
Recently, more concerns have been raised for proton pump inhibitors about the 
risks of acute interstitial nephritis, chronic kidney disease, and end-stage renal 
disease, and similar adverse kidney effects, such as interstitial nephritis and acute 
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renal failure, have been attributed to histamine-2 receptor antagonists [26]. But 
according to a newly published review, these potential adverse effects of PPIs must 
be proven by demonstrable evidence [27].
4.5 Interferon (IFN)
Interferons are cytokines that protect body against viral infections. Exogenous 
interferons are used to treat hepatitis B, hepatitis C and various malignancies (IFN-α), 
multiple sclerosis (IFN-β), and chronic granulomatous disease and malignant 
osteoporosis (IFN-γ). They may cause nephrotic syndrome with histological finding 
of minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS) [5, 
28, 29], and renal vascular injury [28].
4.6 Bisphosphonates
Bisphosphonates are used to prevent bone absorption. The oral forms are used 
to treat osteoporosis and are thought to be nonnephrotoxic. But IV forms (pami-
dronate and zoledronic acid) can cause nephrotoxicity. Some reports reveal MCD 
and FSGS—not otherwise specified (FSGS-NOS) after pamidronate therapy and 
some reveal collapsing—FSGS (C-FSGS) after IV zoledronate therapy [5, 30]. 
According to some reports, zoledronic acid mainly leads to ATN [29]. The severity 
of nephrotoxicity depends on dosing, infusion time, and total number of infusion. 
Ibandronate is thought to be safe for kidneys [30].
4.7 Lithium
Lithium carbonate is generally used to treat bipolar disorder. It causes 
multiple renal side effects, most commonly nephrogenic diabetes insipidus. 
Acute lithium toxicity causes ATN. Chronic lithium toxicity occurs after more 
than 10 years of therapy and most commonly causes chronic tubulointerstitial 
nephritis with distal tubular cysts and sometimes secondary glomerulosclerosis. 
Lithium also causes nephrotic syndrome and histological findings of MCD or 
FSGS. Rarely it leads to end-stage renal disease secondary to lithium-associated 
chronic tubulointerstitial nephropathy. Lithium may also lead to renal tubular 
acidosis and hypercalcemia [5, 29, 31].
4.8 Antiangiogenesis drugs (AADs)
AADs are used for treatment of cancers and neovascular eye disorders such 
as diabetic retinopathy, macular degeneration, and retinal vein occlusion. They 
cause nephrotoxicity by endothelial cell injury and thrombotic microangiopathy 
(TMA) [5, 29]. Clinical manifestations of AAD-associated TMA are proteinuria and 
hypertension [29].
4.8.1 Chemotherapeutic agents
4.8.1.1 Mitomycin-C
Mitomycin-C is an alkylating agent used for treatment of malignancies. It can 
lead to TMA and AKI. AKI is dose-dependent, and the risk of TMA significantly 
increases with the cumulative doses of >60 mg [5, 29]. While TMA can occur during 
therapy, it usually occurs several week, average 75 days, after last dosage [29].
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4.8.1.2 Gemcitabine
Gemcitabine is a pyrimidine antagonist that is used to treat a variety of malig-
nancies. AKI is dose-dependent. Higher cumulative dose and prior exposure to 
other chemotherapeutic drugs increase the risk of TMA [5, 29]. AKI occurs almost 
in all patients treated with gemcitabine. TMA most commonly occurs weeks to 
months after initiation of therapy [29].
4.9 Oxymorphone-hydrochloride
Oral-extended release formulation of oxymorphone-hydrochloride is a long-
acting opioid that is used to treat moderate to severe pain. Some data reveal AKI and 
TMA secondary to IV abuse of the drug [5, 32].
4.10 Levamisole
Levamisole has been used in treatment of pediatric nephrotic syndrome, colon 
cancer, inflammatory bowel disease, and rheumatoid arthritis. It was removed from 
the market due to agranulocytosis side effect. But it is still available in illegal form 
mixed with cocaine. Levamisole may cause antineutrophil cytoplasmic autoanti-
bodies (ANCAs)-associated vasculitis (AAV) [5]. It may also rarely lead to hypona-
tremia, Wegener’s granulomatosis, and renal failure [33].
Also antithyroid drugs such as propylthiouracil, carbimazole, and methimazole, 
and an antihypertensive drug hydralazine may lead to AAV [5].
4.11 Angiotensin-converting enzyme inhibitors (ACE-Is)
Captopril is an ACE inhibitor that is used for treatment of hypertension and 
proteinuria. Kaptopril may be the only ACE-I leading to nephrotic syndrome [5].
4.12 Anabolic androgenic steroids
Anabolic androgenic steroids like testosterone and illicitly used forms may lead 
to CKD [34].
4.13 TNF-α inhibitors
TNF-α inhibitors are biologic agents. Based on renal biopsy and clinical find-
ings, glomerulonephritis associated with systemic vasculitis (GNSV), glomeru-
lonephritis in lupus-like syndrome, and isolated autoimmune renal disorder 
are the subgroups of autoimmune renal diseases that may be caused by TNF-α 
inhibitors [5].
4.14 Gold salts
Gold compounds have been used for treatment of rheumatoid arthritis, psoriatic 
arthritis, and juvenile idiopathic arthritis. Because of side effects, low efficacy, and 
high cost, newer medications take place of gold salts. Parenteral use 0f gold leads to 
proteinuria, and gold-induced proteinuria is an indication of gold discontinuation. 
With oral gold therapy, proteinuria is rare. Renal pathology shows membranous 
glomerulonephritis. This may progress to nephrotic syndrome in patients continu-
ing gold therapy [5, 35, 36].
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4.15 Amphotericin-B
Amphotericin-B is an antifungal agent that is the choice in immunocompro-
mised patients. It causes AKI via the tubular cell toxicity [1].
Amphotericin-B damages membrane integrity by causing pores and increases 
membrane permeability, and this leads to distal renal tubular acidosis [16]. Risk 
factors for nephrotoxicity are similar as any toxic nephropathy, but sodium defi-
ciency is important especially in patients taking diuretic therapy [4]. Preventive 
procedures of amphotericin-B nephrotoxicity include saline hydration before and 
after drug administration, use of liposomal formulations, limiting the duration 
of therapy, and considering a continuous low-dose infusion over a 24 hours' 
period [1].
4.16 Calcineurin inhibitors
Cyclosporine and tacrolimus cause reversible AKI by inducing afferent and 
efferent arteriolar vasoconstrictions. Persistent injury can lead to interstitial fibrosis 
and glomerulosclerosis, and this leads to irreversible chronic nephrotoxicity. 
Tacrolimus may cause TMA [16, 37].
4.17 Cisplatin
Cisplatin may affect glomeruli and distal tubule, but it primarily affects proxi-
mal tubules. It leads to tubular necrosis or tubulointerstitial disease. It may increase 
serum creatinine and decrease GFR and lead to hypomagnesaemia, hyponatremia, 
hypocalcemia, and hypokalemia. When administered with hypertonic saline, 
cisplatin is better tolerated [1, 4, 16].
4.18 Cyclosporin-A
Cyclosporin-A leads to acute reversible and chronic irreversible nephrotoxic-
ity. Acute reversible form is seen most commonly in renal transplant recipients 
and manifests as acute renal failure. Chronic form typically manifests after 1-year 
therapy. Clinical features are marked decline in glomerular filtration rate (GFR), 
hypertension, mild proteinuria, and rarely hematuria [4].
4.19 Ifosfamide
Ifosfamide is an analog of cyclophosphamide [16] and is used in the treat-
ment of solid tumors in both children and adults [1] Cyclophosphamide is not 
nephrotoxic, but ifosfamide is toxic to the tubular cell. It prefers proximal tubular 
toxicity and leads to Fanconi’s syndrome [1, 16]. It may also affect glomerulus and 
decreases GFR. These impairments may lead to clinical manifestations including 
hypophosphatemic rickets, proximal and distal renal tubular acidosis, diabetes 
insipidus, and hypokalemia [1].
4.20 Foscarnet
Foscarnet is used for treatment of resistant cytomegalovirus (CMV) infections. 
It causes acute interstitial nephritis and intratubular crystal formation. Foscarnet 
may chelate with calcium and cause hypocalcemia [16].
11
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4.21 Methotrexate (MTX)
Methotrexate is an antiproliferative and immunomodulating agent that is widely 
used. Its high-dose regimen leads to AKI. It may cause cellular damage or crystal 
nephropathy. Hydration therapy and urine alkalinization can prevent the concentration 
of MTX to become too high in the tubules. Also toxic systemic concentrations caused by 
AKI can be prevented by leucovorin administered 24–48 hours after MTX [1].
4.22 mTOR inhibitors
mTOR inhibitors such as sirolimus or everolimus can worsen any significant 
underlying proteinuria in liver recipients with preexisting chronic renal disease [1].
4.23 Vancomycin
Vancomycin is an antimicrobial agent used in the treatment of Gram-positive 
infections. Vancomycin use is associated with nephrotoxicity. Nephrotoxicity range 
was as high as 50% in the past, but now it ranges about 1.0–42.6% by newer formu-
lations. In addition to common nephrotoxicity risk factors, patients weight exceed-
ing 101.4 kg, daily vancomycin dose over 4 g are also risk factors for vancomycin 
nephrotoxicity [38].
4.24 BRAF inhibitors
The selective BRAF inhibitors vemurafenib and dabrafenib are used to treat 
metastatic melanomas. There are no data reported dabrafenib use causing acute 
kidney injury, but there are a few case series with vemurafenib. The Food and Drug 
Administration Adverse Event Reporting System (FAERS) reports renal toxic effect 
of both agents. Vemurafenib appears more nephrotoxic than dabrafenib. Although 
not clear, they are thought to cause tubular interstitial injury with hypokalemia and 
hyponatremia [39].
4.25 Dekstran
Dekstrans are used for volume replacement therapy and may cause acute kidney 
injury. Therefore, fluid status and urine output should be monitored closely [39].
4.26 EDTA
It is a chelating agent used to get rid of iron from the body. It may produce toxic 
effect that may be fatal. Genitourinary effects of EDTA are nephrosis, nephrotoxic-
ity, occult blood in urine, and proteinuria [40].
5. Contrast-induced nephropathy
Contrast-induced nephropathy is defined as an increase in serum Cr level of 
greater than 0.5 mg/dL or 25% over baseline during a period of 12–48 hours after 
contrast administration and the exclusion of other causes of AKI [2, 41].
Contrast agents generally lead to reversible AKI. Histopathologic evidence 
generally shows ATN. Compared with other types of ATN, contrast nephropathy is 
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usually characterized by relatively rapid recovery of renal function. Most patients 
are nonoliguric. If occurs, oliguria occurs immediately after the procedure. Other 
manifestations of acute kidney injury, such as hyperkalemia, acidosis, and hyper-
phosphatemia, may be present. The urinary sediment may show classical findings 
of ATN. Proteinuria is absent or mild [41].
Underlying chronic renal disease, diabetes, and nephrotoxic medications pre-
dispose patients to renal injury from contrast. If IV contrast is necessary, patients 
can be pretreated with N-acetylcysteine (600 mg twice daily for two doses before 
study and after study) and alkalinized IV hydration (three ampules of 50 mEq 
sodium bicarbonate in 1000 mL D5W solution). In most cases, Cr usually starts to 
decline within 3–7 days. Dialysis is rarely required for contrast-induced AKI [37].
6. Crystal-induced nephropathy
Crystal nephropathies cause mechanical obstruction, local intrarenal inflam-
mation, and tissue injury. There are three subgroups of crystal nephropathies: renal 
ischemic, tubular injury, and obstructive nephropathy [42].
Crystal-induced acute kidney injury commonly occurs following the administra-
tion of drugs or toxins that are poorly soluble or have metabolites that are poorly 
soluble in the urine [3, 43]. Especially in volume depletion status, glomerular 
ultrafiltrate can be enriched with minerals, proteins, or drug metabolites. Acute 
accumulation can induce a sudden onset of crystal formation leading to AKI, and 
long-term accumulation can lead to CKD [3, 42].
Patiens with drug- related crystal- induced AKI are usually asymptomatic. Kidney 
injury usually manifests with increased serum Cr, accompanying with hematuria, 
pyuria, and crystalluria. Crystal-induced AKI is generally reversible by discontinua-
tion of the drug. It may rarely progress to CKD and dialysis may be required.
Risk factors for crystal-induced nephropathies are intravascular volume deple-
tion, underlying kidney or liver disease, and metabolic disturbances that change 
urinary pH [3, 43].
6.1 Sulfonamide antibiotics
Sulfadiazine and sulfamethoxazole are relatively insoluble in acid urine. 
Alkalinization of urine to a pH > 7.15 increases sulfadiazine solubility.
6.2 Methotrexate
High-dose methotrexate can both precipitate in the tubules and cause direct 
tubular injury. Alkalinization of urine to a pH > 7 increases methotrexate solubility. 
Methotrexate-induced acute kidney injury is typically nonoliguric and often reversible.
6.3 Indinavir
It is a protease inhibitor used in the treatment of human immunodeficiency 
virus infection. Acidic urine pH (<6) increases indinavir solubility, but acidification 
of urine may be harmful; thus, it is not recommended.
6.4 Ciprofloxacin
It is a fluoroquinolone antibiotic and causes acute interstitial nephritis and 
crystal-induced nephropathy. Crystals precipitate in alkaline pH [43].
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The other drugs that may lead to crystal-induced nephropathy are acyclovir; 
protease inhibitors such as indinavir, atazanavir; foskarnet; megadose vitamin C; 
orlistat; oral sodium phosphate; purgatives; triamterene; and high-dose amoxicillin 
[2, 3, 16, 43].
6.5 Acyclovir
It is used in the treatment of herpes infections and sepsis in neonates. It can most 
commonly lead to crystal-induced nephrotoxicity and also to nephrotoxicity by 
direct tubular injury [21].
7. Conclusion
Many drugs both prescribed or over-the counter have potential to cause kidney 
damage. Therefore, some basic items such as past medical history, age and weight 
of the patient, drug-related risk factors, and nephrotoxic drug combinations should 
be taken into consideration before starting the treatment. If a nephrotoxic drug use 
is mandatory, patients should be followed up closely and frequently with appropri-
ate biomarkers. Basic renal functions should be evaluated before treatment. The 
early detection of drug-induced nephropathies and application of the appropriate 
treatment methods are critical, because many patients recover when the drug is 
discontinued.
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